TP53 and acute myeloid leukemia: Siremadlin (HDM201) is an orally bioavailable and selective inhibitor of the p53-MDM2 interaction designed by Novartis.1062 Currently, three clinical trials of siremadlin monotherapy or in combination with other drugs for the treatment of patients with advanced soft-tissue sarcoma (NCT05180695), AML (NCT05447663, NCT05155709) are ongoing.